Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

US Personalized Medicine Companies

U.S. Personalized Medicine Companies lead the frontier in tailoring medical treatments to individual genetic profiles, revolutionizing healthcare. Pioneering firms like Illumina, leveraging cutting-edge genomic sequencing, decode unique DNA blueprints to predict disease susceptibility and guide personalized therapies. Foundation Medicine specializes in precision oncology, deciphering tumor genomic data for targeted cancer treatments. 23andMe, a prominent player, provides direct-to-consumer genetic testing, empowering individuals with insights into their health risks.

US Personalized Medicine Key Companies

 

Latest US Personalized Medicine Companies Update


Illumina acquired Grail, Inc. for $8 billion, aiming to strengthen its leadership in cancer genomics and early detection technologies.


Exact Sciences Corporation partnered with Tempus Labs, Inc. to combine their expertise in cancer diagnostics and data analytics, providing comprehensive personalized oncology solutions.


Verily Life Sciences LLC (Alphabet) collaborated with Johnson & Johnson to develop and deploy AI-powered tools for clinical trial matching and patient selection, facilitating personalized drug development.


Foundation Medicine launched its FoundationOne CDx tissue-based assay, enabling comprehensive genomic profiling of tumors for cancer treatment guidance and clinical trial eligibility.


Guardant Health introduced its LUNAR-Dx liquid biopsy test, offering non-invasive detection and monitoring of minimal residual disease in various cancers.


Adaptive Biotechnologies Corporation developed its clonoSEQ assay, providing insights into T-cell receptor (TCR) repertoire for personalized immunotherapy development in cancer and infectious diseases.


List of US Personalized Medicine Key Companies in the Market



  • Laboratory Corporation of America

  • Quest Diagnostics

  • Abbott

  • Becton Dickinson & Co.

  • Siemens Healthcare Diagnostics Inc.

  • GE Healthcare

  • Pfizer Inc.

  • Sanofi

  • CardioDx Inc.

  • Asuragen Inc.

  • Bristol-Myers Squibb


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.